148. Testing Diagnostics for TB
Session: Symposium: Tuberculosis: What's New in Diagnosis and Management
Thursday, October 4, 2018: 11:20 AM
Room: S 214-216
David Alland, MD, Center for Emerging and Re-Emerging Pathogens, Rutgers New Jersey Medical School, Newark, NJ

Dr. Alland received a BA from Columbia University, and an MD from the Columbia College of Physicians and Surgeons. He then completed a Residency in Internal Medicine at Columbia Presbyterian Hospital, and an Infectious Disease Fellowship at Albert Einstein College of Medicine/Montefiore Medical Center. He is currently Professor and Chief of Infectious Disease and the Director of the Center for Emerging Pathogens at Rutgers, New Jersey Medical School. Dr. Alland is internationally recognized for pioneering work on the epidemiology, diagnosis, and evolution of drug resistant Mycobacterium tuberculosis. His seminal paper in the New England Journal of Medicine demonstrated that disease transmission predominated over reactivation of latent infection as a cause for drug-resistant tuberculosis (TB) in New York City. This study helped guide interventions for controlling the US TB epidemic of the 1990s. He then developed a series of break-through diagnostics culminating in the Xpert MTB/RIF Assay, the first on-demand, point-of-care test for TB and rifampin-resistance. Clinically validated in a lead article in the New England Journal of Medicine this test has simplified TB detection and increased the diagnosis of TB and rifampin-resistance notification rates. His newly developed rapid, point-of-care test for resistance to isoniazid, the fluoroquinolones and the injectable anti-tubercular drugs was recently published in the New England Journal of Medicine. Dr. Alland has also contributed to major advancements in our understanding of TB drug tolerance and drug-resistance. He described the first molecular mechanism for drug tolerant M. tuberculosis in the iniBAC operon, and also described the unexpected mutational complexities of the molecular evolution of M. tuberculosis drug resistance in several high profile papers including a key publication in Nature Genetics. These efforts have influenced our understanding of how M. tuberculosis evades drug treatment.


Disclosures:

D. Alland, Cepheid: Grant Investigator , Investigator and Research Contractor , Licensing agreement or royalty and Research grant . Specific Technologies: Collaborator and Scientific Advisor , Research support and stock options .

<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.